Nghiên cứu pha I/II về dược động học và dược gen của calcitriol kết hợp với cisplatin và docetaxel trong ung thư phổi không tế bào nhỏ giai đoạn muộn

Azzoli CG, Temin S, Aliff T, Baker S Jr, Brahmer J, Johnson DH et al (2011) 2011 Focused Update of 2009 American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non-Small-Cell Lung Cancer. J Clin Oncol 29(28):3825–3831 Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J et al (2002) Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346(2):92–98 Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A et al (2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355(24):2542–2550 Deeb KK, Trump DL, Johnson CS (2007) Vitamin D signalling pathways in cancer: potential for anticancer therapeutics. Nat Rev Cancer 7(9):684–700 Hershberger PA, McGuire TF, Yu WD, Zuhowski EG, Schellens JH, Egorin MJ et al (2002) Cisplatin potentiates 1,25-dihydroxyvitamin D3-induced apoptosis in association with increased mitogen-activated protein kinase kinase kinase 1 (MEKK-1) expression. Mol Cancer Ther 1(10):821–829 Liu M, Lee MH, Cohen M, Bommakanti M, Freedman LP (1996) Transcriptional activation of the Cdk inhibitor p21 by vitamin D3 leads to the induced differentiation of the myelomonocytic cell line U937. Genes Dev 10(2):142–153 Rassnick KM, Muindi JR, Johnson CS, Balkman CE, Ramnath N, Yu WD et al (2008) In vitro and in vivo evaluation of combined calcitriol and cisplatin in dogs with spontaneously occurring tumors. Cancer Chemother Pharmacol 62(5):881–891 Fakih MG, Trump DL, Muindi JR, Black JD, Bernardi RJ, Creaven PJ et al (2007) A phase I pharmacokinetic and pharmacodynamic study of intravenous calcitriol in combination with oral gefitinib in patients with advanced solid tumors. Clin Cancer Res 13(4):1216–1223 Trump DL, Hershberger PA, Bernardi RJ, Ahmed S, Muindi J, Fakih M et al (2004) Anti-tumor activity of calcitriol: pre-clinical and clinical studies. J Steroid Biochem Mol Biol 89–90(1–5):519–526 Muindi JR, Wilson JW, Peng Y, Capozolli MJ, Johnson CS, Trump DL (2003) A limited sampling method for the estimation of serum calcitriol area under the curve in cancer patients. J Clin Pharmacol 43(8):894–900 Smith DC, Johnson CS, Freeman CC, Muindi J, Wilson JW, Trump DL (1999) A Phase I trial of calcitriol (1,25-dihydroxycholecalciferol) in patients with advanced malignancy. Clin Cancer Res 5(6):1339–1345 Muindi JR, Peng Y, Potter DM, Hershberger PA, Tauch JS, Capozzoli MJ et al (2002) Pharmacokinetics of high-dose oral calcitriol: results from a phase 1 trial of calcitriol and paclitaxel. Clin Pharmacol Ther 72(6):648–659 Kepner JL, Chang MN (2004) Samples of exact k-stage group sequential designs for Phase II and Pilot studies. Control Clin Trials 25(3):326–333 Fossella F, Pereira JR, von Pawel J, Pluzanska A, Gorbounova V, Kaukel E et al (2003) Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. J Clin Oncol 21(16):3016–3024 Kubota K, Watanabe K, Kunitoh H, Noda K, Ichinose Y, Katakami N et al (2004) Phase III randomized trial of docetaxel plus cisplatin versus vindesine plus cisplatin in patients with stage IV non-small-cell lung cancer: the Japanese Taxotere Lung Cancer Study Group. J Clin Oncol 22(2):254–261 Muindi JR, Johnson CS, Trump DL, Christy R, Engler KL, Fakih MG (2009) A phase I and pharmacokinetics study of intravenous calcitriol in combination with oral dexamethasone and gefitinib in patients with advanced solid tumors. Cancer Chemother Pharmacol 65(1):33–40 Chen G, Kim SH, King AN, Zhao L, Simpson RU, Christensen PJ et al (2011) CYP24A1 is an independent prognostic marker of survival in patients with lung adenocarcinoma. Clin Cancer Res 17(4):817–826 Freireich EJ, Gehan EA, Rall DP, Schmidt LH, Skipper HE (1966) Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man. Cancer Chemother Rep 50(4):219–244 Chadha MK, Tian L, Mashtare T, Payne V, Silliman C, Levine E et al (2010) Phase 2 trial of weekly intravenous 1,25 dihydroxy cholecalciferol (calcitriol) in combination with dexamethasone for castration-resistant prostate cancer. Cancer 116(9):2132–2139 Trump DL, Muindi J, Fakih M, Yu WD, Johnson CS (2006) Vitamin D compounds: clinical development as cancer therapy and prevention agents. Anticancer Res 26(4A):2551–2556 Shen H, Bielak LF, Ferguson JF, Streeten EA, Yerges-Armstrong LM, Liu J et al (2010) Association of the vitamin D metabolism gene CYP24A1 with coronary artery calcification. Arterioscler Thromb Vasc Biol 30(12):2648–2654 Wjst M, Heimbeck I, Kutschke D, Pukelsheim K (2010) Epigenetic regulation of vitamin D converting enzymes. J Steroid Biochem Mol Biol 121(1–2):80–83. doi:10.1016/j.jsbmb.2010.03.056 Muindi JR, Nganga A, Engler KL, Coignet LJ, Johnson CS, Trump DL (2007) CYP24 splicing variants are associated with different patterns of constitutive and calcitriol-inducible CYP24 activity in human prostate cancer cell lines. J Steroid Biochem Mol Biol 103(3–5):334–337 Roff A, Wilson RT (2008) A novel SNP in a vitamin D response element of the CYP24A1 promoter reduces protein binding, transactivation, and gene expression. J Steroid Biochem Mol Biol 112(1–3):47–54 St-Arnaud R, Arabian A, Travers R, Barletta F, Raval-Pandya M, Chapin K et al (2000) Deficient mineralization of intramembranous bone in vitamin D-24-hydroxylase-ablated mice is due to elevated 1,25-dihydroxyvitamin D and not to the absence of 24,25-dihydroxyvitamin D. Endocrinology 141(7):2658–2666